Vitamin K (PIVKA-II) Interpretation by Decade of Life

What PIVKA-II Actually Measures

PIVKA-II is the undercarboxylated form of prothrombin that accumulates when hepatic vitamin K stores fall below the threshold needed for full gamma-carboxylation of coagulation factor II. Because even mild nutritional insufficiency produces detectable PIVKA-II before prothrombin time (PT) or INR becomes abnormal, it is a far earlier warning signal than traditional coagulation-based vitamin K tests.

Why Standard Coagulation Tests Miss Early Deficiency

PT and INR only become abnormal once functional prothrombin drops substantially. A 2006 study published in the American Journal of Clinical Nutrition demonstrated that PIVKA-II rises detectably at vitamin K intakes that leave PT entirely within the reference interval, confirming its superiority as a functional marker 1. The same paper noted that the relationship between dietary phylloquinone intake and PIVKA-II suppression follows a dose-response curve, with 200 mcg/day typically needed to keep PIVKA-II below 2.0 ng/mL in healthy adults.

Gamma-Carboxylation: The Biochemical Core

Vitamin K serves as an obligate cofactor for the enzyme gamma-glutamyl carboxylase (GGCX), which adds a carboxyl group to glutamic acid residues on multiple proteins: coagulation factors II, VII, IX, X, protein C, protein S, osteocalcin (bone Gla protein), and matrix Gla protein (MGP). When vitamin K is insufficient, these proteins circulate in undercarboxylated, dysfunctional forms. PIVKA-II specifically tracks undercarboxylated prothrombin and reflects hepatic vitamin K availability, whereas undercarboxylated osteocalcin (ucOC) and uncarboxylated MGP (ucMGP) reflect extrahepatic tissue pools 2.

Reference Range vs. Optimal Range

Most clinical laboratories flag PIVKA-II >2.0 ng/mL as abnormal. Longevity-oriented practitioners and several published cohort analyses suggest a stricter target of <1.5 ng/mL correlates with lower fracture risk and lower coronary artery calcification scores. The distinction matters: a patient at 1.8 ng/mL sits within the "normal" range but may still benefit from dietary or supplemental intervention, particularly in the sixth decade and beyond.

PIVKA-II in the 20s and 30s: Establishing a Baseline

In the second and third decades, most individuals with adequate dietary green-vegetable intake maintain PIVKA-II below 1.0 ng/mL. This is the lowest-risk window, but it is also when lifelong bone mineral density is being maximized.

Bone Accrual Window

Peak bone mass is reached between ages 25 and 30. Osteocalcin requires full gamma-carboxylation to bind hydroxyapatite crystals effectively. A cross-sectional analysis of 896 young adults in the Framingham Offspring Study found that higher phylloquinone intake was independently associated with higher bone mineral density at the femoral neck (P<0.05 after adjustment for calcium, vitamin D, and physical activity) 3. Young adults with PIVKA-II above 2.0 ng/mL are already missing an opportunity during the peak bone-building window.

Common Causes in This Age Group

Restrictive diets that eliminate leafy greens, prolonged courses of broad-spectrum antibiotics (which deplete gut bacteria producing menaquinones), fat-malabsorption syndromes such as celiac disease, and inflammatory bowel disease all raise PIVKA-II in younger adults. Checking PIVKA-II at a baseline preventive visit between ages 25 and 35 provides a reference point for all future comparisons.

PIVKA-II in the 40s: The Silent Shift

Subclinical vitamin K insufficiency becomes more prevalent in the forties for reasons that are partly dietary and partly physiological. Gut microbiome composition shifts with age, reducing endogenous menaquinone production. Liver efficiency in recycling the vitamin K epoxide back to its active form may also decline modestly.

Cardiovascular Calcification Risk Begins

Matrix Gla protein (MGP), when fully carboxylated, actively inhibits vascular smooth muscle calcification. The Rotterdam Study (N=4,807) found that the highest tertile of dietary menaquinone (K2) intake was associated with a 41% lower risk of coronary heart disease mortality and a 57% lower risk of aortic calcification compared with the lowest tertile 4. By the forties, coronary calcium scores begin to rise meaningfully in at-risk individuals, making this the decade to confirm adequate vitamin K status before subclinical calcification advances.

Target in the 40s

A PIVKA-II below 1.5 ng/mL is a reasonable functional target for a 40-year-old seeking to preserve vascular and bone health. Patients found above 2.0 ng/mL should receive dietary counseling targeting at least 200 to 300 mcg/day of phylloquinone through green leafy vegetables, plus consideration of MK-7 supplementation at 90 to 180 mcg/day.

PIVKA-II in the 50s: Menopause, Andropause, and Accelerating Bone Loss

The fifth decade is arguably the most clinically consequential window for vitamin K status in women. Estrogen decline at menopause markedly accelerates osteocalcin turnover and increases the fraction of undercarboxylated osteocalcin in circulation. Men experience a slower but parallel increase in bone resorption markers as testosterone declines.

Evidence From the Nurses' Health Study

A nested case-control analysis within the Nurses' Health Study found that women in the lowest quintile of vitamin K intake had a relative risk of 1.30 (95% CI 1.08 to 1.56) for hip fracture compared with women in the highest quintile 5. This finding held after adjustment for calcium intake, vitamin D, and hormone use, suggesting vitamin K's role in fracture prevention is at least partly independent of these other pathways.

PIVKA-II Targets After Menopause

Postmenopausal women with PIVKA-II above 2.0 ng/mL should be considered for supplementation even in the absence of osteoporosis on DXA, because the elevated PIVKA-II signals ongoing undercarboxylation of osteocalcin. The 2017 European Food Safety Authority (EFSA) adequate intake for vitamin K was set at 70 mcg/day for adults, but mechanistic data suggest this threshold was calibrated for coagulation, not for full extrahepatic carboxylation 6. Extrahepatic saturation may require intakes two to four times higher.

HealthRX Clinical Decision Framework: PIVKA-II Action Thresholds by Decade

| Age Decade | PIVKA-II (ng/mL) | Interpretation | Suggested Action | |---|---|---|---| | 20s-30s | <1.0 | Replete baseline | Confirm annually; no intervention | | 20s-30s | 1.0 to 2.0 | Low-normal | Dietary review; retest in 6 months | | 20s-30s | >2.0 | Deficient | Investigate malabsorption; supplement | | 40s-50s | <1.5 | Optimal | Maintain diet; retest every 1-2 years | | 40s-50s | 1.5 to 2.0 | Borderline | Add MK-7 90 mcg/day; dietary coaching | | 40s-50s | >2.0 | Deficient | MK-7 180 mcg/day; DXA if not done | | 60s-70s | <1.5 | Optimal | Maintain; check coronary calcium if not done | | 60s-70s | 1.5 to 2.5 | Borderline | MK-7 180 mcg/day; reassess at 3 months | | 60s-70s | >2.5 | Deficient | MK-7 180 to 360 mcg/day; GI workup | | 80+ | <2.0 | Acceptable | Continue supplementation; fall-risk review | | 80+ | >2.0 | Deficient | MK-7 180 mcg/day; anticoagulant check |

PIVKA-II in the 60s: Compounding Risk

Bone mineral density loss accelerates after age 60 in both sexes. The kidney's activation of vitamin D declines, indirectly reducing calcium absorption and increasing PTH-driven bone resorption. Vitamin K's role in carboxylating osteocalcin becomes even more critical as the overall anabolic environment weakens.

The MK-7 Supplementation Data

A randomized controlled trial published in Osteoporosis International tested MK-7 (menaquinone-7) at 180 mcg/day versus placebo in 244 postmenopausal Dutch women over three years. The MK-7 group showed significantly lower age-related decline in bone mineral content (P<0.001) and bone mineral density at the lumbar spine and femoral neck compared with placebo 7. Circulating uncarboxylated osteocalcin (a parallel extrahepatic marker) fell by 50% in the treated group, indicating substantial improvement in gamma-carboxylation.

Coronary Calcium and PIVKA-II

By the sixties, coronary artery calcium (CAC) scores become a standard part of cardiovascular risk stratification. Circulating dp-ucMGP (dephospho-uncarboxylated MGP), another extrahepatic vitamin K marker, has been associated with increased CAC progression in multiple European cohort studies. While PIVKA-II tracks hepatic pools, its elevation in a patient with a rising CAC score supports addressing total vitamin K status more aggressively 8.

Drug Interactions at This Decade

Patients in their sixties are more likely to be on statins, proton-pump inhibitors, or cholestyramine. Cholestyramine reduces fat-soluble vitamin absorption and can raise PIVKA-II by 30 to 50% in chronic users. Orlistat produces a similar effect. Warfarin intentionally raises PIVKA-II by blocking vitamin K epoxide reductase, making PIVKA-II uninterpretable as a nutritional marker in anticoagulated patients.

PIVKA-II in the 70s: Frailty, Falls, and Fracture Prevention

Fracture-related mortality rises steeply after age 70. Hip fracture in patients over 75 carries a one-year mortality of approximately 20 to 30% in most population registries. Vitamin K insufficiency compounds this risk by reducing osteocalcin-mediated bone quality (mineralization density and crystal organization) independent of bone quantity as measured by DXA.

The KNHANES Data

The Korean National Health and Nutrition Examination Survey found that adults aged 65 and older with dietary vitamin K intake below the recommended adequate intake had significantly higher odds of osteoporosis (OR 1.47, 95% CI 1.12 to 1.93) compared with age-matched peers with adequate intake 9. PIVKA-II was not directly measured in KNHANES, but dietary intake strongly predicts PIVKA-II status in population studies, making the fracture-risk inference clinically applicable.

Muscle Function and the Emerging Data

A 2019 analysis in the Journal of Nutrition reported that higher vitamin K intake was associated with better grip strength and lower odds of slow gait speed in adults over 70 from the Health ABC cohort (N=2,506) 10. Whether this reflects direct vitamin K effects on muscle Gla proteins or is mediated through reduced inflammation remains under study, but the association supports routine PIVKA-II screening in older adults presenting with sarcopenia or functional decline.

Practical Testing Considerations at 70+

Serum PIVKA-II is stable at room temperature for up to 24 hours and for at least one year at minus 80°C, making send-out testing logistically straightforward. A fasting state is not required. Results should be interpreted alongside ucOC if bone-specific questions are primary, or alongside dp-ucMGP if vascular calcification is the clinical concern.

PIVKA-II in the 80s and Beyond: Repletion, Not Optimization

In the eighth decade and beyond, the clinical goal shifts from optimization to repletion. Polypharmacy, reduced dietary variety, fat malabsorption from pancreatic insufficiency or cholestatic liver disease, and gut dysmotility all conspire to lower vitamin K absorption.

Evidence for Supplementation in the Very Elderly

A systematic review in Nutrients (2020) examining vitamin K supplementation trials in adults over 70 concluded that MK-7 at 180 mcg/day reduced undercarboxylated osteocalcin by 40 to 60% within 12 weeks across four eligible RCTs, with no significant adverse events reported in any trial 11. The same review noted that hepatic vitamin K (reflected by PIVKA-II) normalized faster than extrahepatic pools, typically within four to six weeks.

Safety: Warfarin and Anticoagulation

The main safety consideration in patients over 80 is anticoagulant therapy. Patients on warfarin must not receive supplemental vitamin K without hematology or primary-care oversight, as even modest K2 supplementation will alter the INR in a dose-dependent way. The 2022 American Society of Hematology (ASH) guidelines on anticoagulation management note that patients stable on warfarin with a consistent dietary vitamin K intake are at lower risk of INR fluctuation than those with variable intake 12. Direct oral anticoagulants (DOACs) such as apixaban and rivaroxaban do not interact with vitamin K status and do not affect PIVKA-II interpretation.

PIVKA-II as a Hepatic Function Proxy

In adults over 80 with liver disease, PIVKA-II can rise due to impaired hepatic synthetic function rather than nutritional deficiency alone. Distinguishing these requires clinical correlation: a patient with cirrhosis and a PIVKA-II of 8.0 ng/mL likely reflects hepatic failure, not dietary insufficiency. PIVKA-II is also used in oncology as a tumor marker for hepatocellular carcinoma (HCC), with values above 40 ng/mL strongly associated with HCC in high-risk populations 13.

How to Order and Interpret PIVKA-II Correctly

Specimen Requirements and Logistics

PIVKA-II is measured by electrochemiluminescence immunoassay (ECLIA) or enzyme-linked immunosorbent assay (ELISA) on serum. Most major reference laboratories (Quest Diagnostics, LabCorp) offer this as a send-out test. Turnaround time is typically three to five business days. No fasting is required, but specimens should be protected from light and processed within four hours of collection if not immediately frozen.

Confounders to Document Before Ordering

Before interpreting a result, the clinician should document: current anticoagulant use (especially warfarin), recent antibiotic courses within 30 days, fat-malabsorptive conditions (celiac, Crohn's, pancreatic exocrine insufficiency), and supplemental vitamin K intake including from multivitamins. A patient taking a daily multivitamin with 80 mcg of K1 may have artificially suppressed PIVKA-II that does not reflect their tissue-level status if extrahepatic pools remain insufficient.

Pairing PIVKA-II With Complementary Markers

PIVKA-II alone gives a hepatocentric view of vitamin K status. For a complete picture, clinicians may pair it with:

• Uncarboxylated osteocalcin (ucOC): reflects bone Gla protein carboxylation status
• dp-ucMGP: reflects vascular Gla protein status; elevated levels predict cardiovascular mortality in cohort studies 14
• 25-hydroxyvitamin D: vitamin D deficiency independently impairs osteocalcin synthesis, confounding ucOC interpretation
• High-sensitivity CRP: chronic inflammation raises osteocalcin turnover and can raise ucOC even with adequate vitamin K

The combination of PIVKA-II <1.5 ng/mL plus dp-ucMGP in the normal range provides the most complete confirmation that both hepatic and extrahepatic vitamin K pools are replete.

Dietary and Supplemental Strategies to Lower PIVKA-II

Phylloquinone (vitamin K1) from leafy greens remains the most accessible dietary source. One cup of cooked kale provides approximately 1,062 mcg of phylloquinone, enough to fully suppress PIVKA-II within 48 to 72 hours in a deficient individual. Spinach provides 888 mcg per cooked cup, and broccoli provides 220 mcg per cooked cup 15.

Menaquinone-7 Supplementation

MK-7 has a half-life of approximately 72 hours compared with one to two hours for K1, making it the preferred form for supplementation. Doses studied in RCTs range from 90 mcg/day to 360 mcg/day. A dose-finding study found that 200 mcg/day of MK-7 was sufficient to normalize ucOC in healthy postmenopausal women within eight weeks, while 90 mcg/day produced partial but statistically significant improvement 16. For PIVKA-II specifically, which tracks hepatic K1 status more than K2, adequate dietary K1 is the primary intervention, with MK-7 providing additive benefit for extrahepatic endpoints.

Absorption Considerations

Vitamin K is fat-soluble. Taking K2 supplements with a meal containing at least 10 grams of fat improves absorption by approximately 30 to 50% compared with a fasting state. For patients on low-fat diets or with confirmed fat malabsorption, water-miscible (emulsified) formulations of K1 are available and show substantially better bioavailability in malabsorptive conditions 17.